Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301760 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPCYP3A4 | |
| SCHEMBL3306913 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPCYP3A4 | |
| SCHEMBL3304466 | 0.86 | CYP3A4 (0.39) | CYP3A4MAPTKDM4EALDH1A1 | |
| SCHEMBL3305703 | 0.86 | CYP3A4 (0.39) | CYP3A4MAPTKDM4EALDH1A1 | |
| SCHEMBL3303578 | 0.81 | CHRM2 (0.36) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL6922250 | 0.77 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPCYP3A4 | |
| SCHEMBL3303849 | 0.76 | GPR119 (0.35) | HSD11B1GPR119 | |
| SCHEMBL6328311 | 0.72 | NR1H2 (0.34) | CYP3A4NR1H2KDM4E | |
| SCHEMBL5819619 | 0.72 | NR1H2 (0.41) | CHRM2CHRM1CHRM3PREPCYP3A4 | |
| SCHEMBL6363601 | 0.72 | NR1H2 (0.41) | CHRM2CHRM1CHRM3PREPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | MARTINEZ-PEREZ JOSE ANTONIO | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, GRIN1 | CHRM2 513/4885CHRM1 338/4885CHRM3 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.